Santa Fe mayor speaks on city's efforts to address homelessness
Officials speak on wildfire that damaged Fort Stanton Historic Sit
In 2019, Santa Fe joined a coalition called Built for Zero, which is a national movement where city officials try to build enough housing for their homeless population so that zero people are left without homes. A unique way they continue to address homelessness is by learning the names and history of the city's homeless population. 'When you know their names, you work with them individually to get the solution that fits their needs,' said Mayor Webber.
The city is looking for more properties to implement microcommunities.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
After Mecklenburg County's transportation bill passes Senate, do Charlotte residents support the tax hike?
CHARLOTTE, N.C. (QUEEN CITY NEWS) — Mecklenburg County's transportation bill, also known as the P.A.V.E Act, is on the governor's desk awaiting his signature. It will then be up to local leaders to garner support of the one-cent transit sales tax. Gov. Josh Stein is reviewing the P.A.V.E Act now and will have 10 days to take action on it. After getting his approval, it's going to be all hands on deck for Mecklenburg County officials, who have between now and November to convince voters to stand behind the sales tax. 'I want to know how that plan will impact the area where I live right now,' said Wendy Pascual, who lives in east Charlotte. Many people are asking how this will affect them, as they work to figure out where they stand on the proposal. CATS adds 100+ new vehicles to its fleet, improving customer comfort and reliability 'What is that they want to do with the thing and how will that impact the community and to be able to make a decision and decide if I want to support it or not,' said Pascual. While some aren't on board yet, others are full-steam ahead 'I think it's more than worth it,' said David Thomas, who lives in east Charlotte. 'We got to make this investment and we don't put the money in and the city's economy can hurt from that.' Dozens of east Charlotte residents gathered at a town hall hosted by Charlotte City Councilwoman Marjorie Molina on Thursday. They were there to learn more about the tax referendum, which is expected to generate nearly $20 billion over the next 30 years. 'Right now, I think we do have a pretty short runway right to get our community members up to date,' said Molina. Officials detail plans to improve Mecklenburg County bus stops, but they need a one-cent sales tax to do it Charlotte leaders recognize the hurdles they face over the next few months to sell people on the idea. They're optimistic they can get it done. 'People don't want to pay more taxes, and referendums in other cities have been unsuccessful on occasion like this,' said Councilman Ed Driggs. 'On the other hand, everybody sees the condition on the roads, and I think the story that we're telling about the advantages that they can expect, the rail, the bus, the roads, sidewalks, bike trails. I think people will get excited about that.' Mecklenburg County commissioners will have to hold a vote before the election in order to get the extra tax on the ballot. It's unclear right now when that will happen. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Newsweek
4 hours ago
- Newsweek
Chocolate Recalled in Eight States as 'Life-Threatening' Warning Issued
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Wegmans Semi-Sweet Chocolate Nonpareils have been recalled from stores in eight states and Washington, D.C., following the discovery of undeclared milk allergens in the product's packaging. The recall, announced by Mellace Family Brands California, Inc. on June 25, encompasses specific batches sold at Wegmans retail locations in Delaware, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania, Virginia, and the D.C. "People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product," the company said. Why It Matters Food recalls due to undeclared allergens continue to be a critical public health issue in the United States. Individuals with milk allergies face the constant risk of accidental exposure to this common allergen, which can cause serious—and sometimes fatal—reactions. What To Know Mellace Family Brands California, Inc. recalled Wegmans Semi-Sweet Chocolate Nonpareils after discovering the product contained undeclared milk allergens. The recall applies to 18.5-ounce containers labeled with the following best by and lot codes: 55021 BEST BY: DEC 28, 2025 55031 BEST BY: DEC 29, 2025 55491 BEST BY: FEB 13, 2026 55501 BEST BY: FEB 14, 2026 56061 BEST BY: APR 11, 2026 56071 BEST BY: APR 12, 2026 The product features UPC 0 77890 49787 6. The issue was attributed to a temporary breakdown in the supplier's manufacturing process, resulting in the presence of milk in products labeled as milk-free. As of June 30, no illnesses have been reported, according to the company. Consumers who have purchased Wegmans Semi-Sweet Chocolate Nonpareils with the above lot codes are "urged to return them to the place of purchase for a full refund," according to the company announcement published by the Food and Drug Administration (FDA) on Monday. What People Are Saying Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." Recalled Wegmans Semi-Sweet Chocolate Nonpareils products Recalled Wegmans Semi-Sweet Chocolate Nonpareils products FDA What Happens Next Customers with questions can contact Wegmans Food Markets at 1-855-934-3663 daily from 8 a.m. to 8 p.m. ET. The FDA encourages anyone experiencing symptoms of an allergic reaction after consuming these products to seek medical attention and submit a report through its online complaint system.
Associated Press
8 hours ago
- Associated Press
Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ('Envoy Medical'), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: 'These latest patent issuances continue to expand the depth and breadth of our intellectual property and reflect our commitment to advancing hearing technology that is integrated into patients' lives,' said Brent Lucas, CEO of Envoy Medical. 'Our team remains focused on delivering differentiated solutions that move the industry forward and are designed to meet the real-world needs of people living with hearing loss.' Envoy Medical's fully implanted technologies are designed to eliminate external components and leverage the natural anatomy of the ear for sound detection, offering a fundamentally different experience from traditional hearing aids or partially implanted systems. For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit To be added to the Envoy Medical email distribution list, please email [email protected] with COCH in the subject line. About Envoy Medical, Inc. Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life. About the Fully Implanted Acclaim® Cochlear Implant We believe the fully implanted Acclaim Cochlear Implant ('Acclaim CI') is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. *Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use. Important safety information for the Esteem FI-AMEI can be found at: Additional Information and Where to Find It Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'will,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'target' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward Looking Statements' in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical. ### Investor Contact: Phil Carlson KCSA Strategic Communications O: 212.896.1233 E: [email protected] SOURCE: Envoy Medical, Inc. To view the source version of this press release, please visit
